English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Recently, the number of diabetic patients has increased very rapidly and is accompanied by an increasing development of diabetic neuropathies (DNs). The incidence and prevalence of DNs associated with duration of diabetes affects up to 50% of diabetic patients after 25 years of disease. Although DNs are known as the most common complications of diabetes, they was not adequately and properly diagnosed, and their severity is not estimated reliably in clinical practice by current methods. DNs have a wide variability in prevalence, from a few percentage points to over 50%. This could be explained by a lack of consensus about defining criteria; lack of sensitive, objective and quantitative diagnostic tools; and lack of homogeneity in research subjects of DNs. In addition, we do not have accurate and reproducible clinical end-point assessment modalities by each researcher. The importance of accurate and early detection of DNs is emphasized by the prediction of all-cause and disease-specific mortality in patients with diabetes accompanied with intensive glycemic control.

Can nerve conduction studies detect earlier and predict clinical diabetic neuropathy?